000180230 001__ 180230
000180230 005__ 20240229145610.0
000180230 0247_ $$2pmid$$apmid:35667092
000180230 0247_ $$2ISSN$$a1055-9965
000180230 0247_ $$2ISSN$$a1538-7755
000180230 0247_ $$2doi$$a10.1158/1055-9965.EPI-22-0092
000180230 0247_ $$2doi$$aDOI: 10.1158/1055-9965.EPI-22-0092
000180230 0247_ $$2altmetric$$aaltmetric:129365544
000180230 037__ $$aDKFZ-2022-01181
000180230 041__ $$aEnglish
000180230 082__ $$a610
000180230 1001_ $$aOse, Jennifer$$b0
000180230 245__ $$aPre-surgery adhesion molecules and angiogenesis biomarkers are differently associated with outcomes in colon and rectal cancer: Results from the ColoCare Study.
000180230 260__ $$aPhiladelphia, Pa.$$bAACR$$c2022
000180230 3367_ $$2DRIVER$$aarticle
000180230 3367_ $$2DataCite$$aOutput Types/Journal article
000180230 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1662122294_29854
000180230 3367_ $$2BibTeX$$aARTICLE
000180230 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000180230 3367_ $$00$$2EndNote$$aJournal Article
000180230 500__ $$a2022 Aug 2;31(8):1650-1660
000180230 520__ $$aCell-to-cell adhesion and angiogenesis are hallmarks of cancer. No studies have examined associations of adhesion-molecules and angiogenesis biomarkers with clinical outcomes in colorectal cancer (CRC).In pre-surgery serum from n=426 CRC patients (stage I-III) we investigated associations of CRP, SAA, adhesion molecules (sICAM-1, sVCAM-1), and angiogenesis markers (VEGF-A, and -D) with overall survival (OS), disease-free survival (DFS), and risk of recurrence. We computed hazard ratios (HR) and 95% confidence intervals; adjusted for age, sex, BMI, stage, site, and study site, stratified by tumor site in exploratory analyses.N=65 (15%) were deceased, 59 patients (14%) had a recurrence after a median follow-up of 31 months. We observed significant associations of biomarkers with OS, DFS, and risk of recurrence on a continuous scale and comparing top to bottom tertile, with HRs ranging between 1.19 - 13.92. CRP was associated with risk of death and recurrence in patients in the top tertile compared to patients in the bottom tertile, e.g., risk of recurrence HRQ3-Q1:13.92 (1.72, 112.56). Significant heterogeneity between biomarkers and clinical outcomes was observed in stratified analysis by tumor site for CRP, SAA, sICAM-1, sVCAM-1, and VEGF-D. VEGF-D was associated with a 3-fold increase in risk of death for rectal cancer (HRlog2: 3.26; 95% CI: 1.58-6.70) compared to no association for colon cancer (HRlog2: 0.78; 95% CI: 0.35-1.73; pheterogenity =0.01).Adhesion molecules and angiogenesis biomarkers are independent prognostic markers for CRC, with differences by tumor site.There is need for tailored treatment for colon and rectal cancer.
000180230 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000180230 588__ $$aDataset connected to DataCite, PubMed, , Journals: inrepo02.dkfz.de
000180230 7001_ $$aGigic, Biljana$$b1
000180230 7001_ $$00000-0003-0292-6168$$aHardikar, Sheetal$$b2
000180230 7001_ $$00000-0001-5147-8432$$aLin, Tengda$$b3
000180230 7001_ $$00000-0003-4084-8340$$aHimbert, Caroline$$b4
000180230 7001_ $$00000-0003-1772-8332$$aWarby, Christy A$$b5
000180230 7001_ $$00000-0003-3645-3960$$aPeoples, Anita R$$b6
000180230 7001_ $$00000-0001-6156-254X$$aLindley, Clara L$$b7
000180230 7001_ $$00000-0001-8639-3543$$aBoehm, Juergen$$b8
000180230 7001_ $$0P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86$$aSchrotz-King, Petra$$b9$$udkfz
000180230 7001_ $$00000-0001-8040-3341$$aFigueiredo, Jane C$$b10
000180230 7001_ $$00000-0003-1079-2606$$aToriola, Adetunji T$$b11
000180230 7001_ $$00000-0003-1779-2510$$aSiegel, Erin M$$b12
000180230 7001_ $$00000-0003-1543-0743$$aLi, Christopher I$$b13
000180230 7001_ $$00000-0003-1469-2186$$aUlrich, Alexis$$b14
000180230 7001_ $$aSchneider, Martin$$b15
000180230 7001_ $$00000-0002-5670-423X$$aShibata, David$$b16
000180230 7001_ $$00000-0001-7641-059X$$aUlrich, Cornelia M$$b17
000180230 773__ $$0PERI:(DE-600)2036781-8$$a10.1158/1055-9965.EPI-22-0092$$n8$$p1650-1660$$tCancer epidemiology, biomarkers & prevention$$v31$$x1055-9965$$y2022
000180230 909CO $$ooai:inrepo02.dkfz.de:180230$$pVDB
000180230 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000180230 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000180230 9141_ $$y2022
000180230 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-02
000180230 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-02-02
000180230 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-02
000180230 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-10
000180230 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-10
000180230 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-10
000180230 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-10
000180230 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-10
000180230 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-10
000180230 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER EPIDEM BIOMAR : 2021$$d2022-11-10
000180230 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-10
000180230 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2022-11-10
000180230 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x0
000180230 980__ $$ajournal
000180230 980__ $$aVDB
000180230 980__ $$aI:(DE-He78)C120-20160331
000180230 980__ $$aUNRESTRICTED